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Introduction
Thrombosis describes the formation of a clot within a blood vessel 
that reduces blood flow and may cause infarction of tissues sup-
plied by that vessel. The most common forms of occlusive throm-
bosis occur in arteries and lead to myocardial infarction and stroke 
(1). Deep vein thrombosis (DVT) mostly occurs in the legs and is 
associated with pulmonary embolism (PE); collectively, these are 
termed venous thromboembolism (VTE) (2). The incidence of VTE 
in industrialized countries is 1–3 individuals per 1,000 per year 
(3–8). Importantly, there is a dramatic increase in the risk of VTE 
above the age of 50, and it reaches as high as 1 in every 100 indi-
viduals annually (3). These alarming statistics led the US Senate 
to designate March as “DVT Awareness Month” in 2005 and the 
Surgeon General’s call to action to prevent DVT and PE in 2008.
There are many genetic and acquired risk factors that are associ-
ated with VTE and recurrent VTE (reviewed in refs. 8–11). Strong 
genetic risk factors that lead to a hypercoagulable state include 
deficiencies in the anticoagulants antithrombin, protein C, and 
protein S. Moderate genetic risk factors include factor V (FV) 
Leiden, prothrombin G20210A, fibrinogen C10034T and non–
type O blood. FV Leiden is present in approximately 5% of people 
of mixed European descent and is a variant of FV that is resistant 
to inactivation by activated protein C. Prothrombin G20210A is 
single nucleotide polymorphism in the 3′ untranslated region of 
the prothrombin gene that leads to increased expression. Fibrino-
gen C10034T is a fibrinogen gamma-chain gene variant that leads 
to reduced levels of the alternatively spliced form of the fibrinogen 
gamma-chain that is associated with increased venous thrombo-
sis (8). Finally, individuals with non–type O blood have increased 
clearance of von Willebrand factor (vWF). Since FVIII circulates in 
plasma bound to vWF, a reduction in plasma vWF is also associ-
ated with reduced levels of FVIII.
Acquired risk factors include age, surgery, obesity, cancer, preg-
nancy, hormone-based contraceptives, hormone replacement, 
antiphospholipid syndrome, acute infection, immobilization, 
paralysis, long-haul travel, smoking, hospitalization, reduced 
fibrinolysis, and acquired thrombophilia (increased levels of pro-
coagulant factors and/or decreased levels of anticoagulant factors) 
(12–30). Obesity has a high prevalence in the US and Western 
countries (15, 25, 29), and one study showed that obesity (body 
mass index ≥ 30 kg/m2) increased the risk of thrombosis 2 fold 
(25). Another study analyzed the risk associated with oral contra-
ceptives with or without FV Leiden and found that the incidence 
of thrombosis was increased 4 fold in individuals taking hormone 
contraceptives, 7 fold in those with FV Leiden, and 36 fold in 
individuals with both risk factors (24). This study demonstrated 
remarkable synergy of these risk factors. A VTE risk scoring model 
has been established for ambulatory patients with cancer based 
on 5 parameters (tumor site, leukocyte count, platelet count, body 
mass index, and either low hemoglobin and/or use of erythropoi-
esis-stimulating agents) (31). Symptomatic VTE was observed in 
0.6% of patients with a score of 0 compared with 6.9% of patients 
with a score of 3 or higher. A recent study extended this scoring 
system to include the biomarkers D-dimer and P-selectin and 
found that patients with the highest score had a cumulative VTE 
probability after 6 months of 35% compared with a probability of 
1% for those patients with the lowest score (32).
Clot formation
A blood clot contains a mixture of platelets and fibrin and in some 
cases red blood cells (1, 33). Importantly, the etiologies of arterial 
and venous clots are very different (1). Arterial clots are formed 
under high shear stress, typically after rupture of an atheroscle-
rotic plaque or other damage to the blood vessel wall (34–36). They 
are platelet-rich (so called “white clots”) and are generally treated 
with antiplatelet drugs. In contrast, venous clots form under lower 
shear stress on the surface of a largely intact endothelium (36–39). 
They are fibrin-rich (so called “red clots” because they also contain 
red blood cells) and are treated with anticoagulant drugs.
The blood coagulation cascade can be divided into three parts: 
the extrinsic, intrinsic, and common pathways (Figure 1 and 
reviewed in refs. 39–42). Under pathological conditions, tissue 
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factor (TF) is expressed on circulating leukocytes and possibly 
activated endothelial cells (40). In addition, TF is present on 
microvesicles (MVs), which are small membrane vesicles released 
from activated cells (43–45). These intravascular sources of TF 
may trigger the formation of venous clots. Recent studies have 
shown that FXII can be activated by extracellular RNA and poly-
phosphates and this activation of the intrinsic pathway may also 
contribute to venous thrombosis (46–49).
The coagulation cascade is regulated at several levels by differ-
ent anticoagulant pathways (50). TF pathway inhibitor blocks the 
TF/FVIIa complex, whereas antithrombin inhibits all coagulation 
proteases, including thrombin (51, 52). Binding of thrombin to 
thrombomodulin on the surface of endothelial cells changes its 
substrate specificity from fibrinogen to protein C and therefore 
plays a key role in shutting down the clotting cascade (53). Bind-
ing of protein C to the endothelial cell protein C receptor enhances 
its conversion to activated protein C, which in association with 
its cofactor protein S, cleaves and inactivates both FVa and FVIIIa 
(54). Importantly, loss of a single anticoagulant pathway leads to 
embryonic lethality (50). One explanation for this observation is 
that different tissues use distinct anticoagulant pathways to regu-
late clotting (50, 55). Clots in blood vessels are removed by pro-
teolytic digestion of fibrin by plasmin (56). Levels of plasmin are 
regulated by plasminogen activators and inhibitors, particularly 
plasminogen activator inhibitor 1 (PAI-1) (57). This explains why 
elevated levels of PAI-1 are associated with thrombosis (8).
Traditionally, VTE is treated with anticoagulant drugs to pre-
vent growth and embolization of the thrombus. Patients initially 
receive some form of injectable heparin, which acts rapidly, fol-
lowed by a more prolonged course of an oral vitamin K antagonist 
(58–60). These drugs have been used for over 50 years. Heparins 
inhibit FXa and thrombin in an antithrombin-dependent manner, 
whereas vitamin K antagonists reduce the activity of vitamin K– 
dependent proteins, including FVIIa, FIXa, FXa, and thrombin. 
The limitations of these drugs have fueled the search for new anti-
coagulant therapies. Over the past 5 years, several new oral drugs 
have been developed, the two most advanced of which are rivar-
oxaban (Xarelto), which selectively inhibits FXa, and dabigatran 
etexilate (Pradaxa), which selectively inhibits thrombin (Figure 1 
and refs. 61–65). Rivaroxaban was shown to be superior to the 
low-molecular-weight heparin enoxaparin in reducing VTE in 
four clinical trials involving total knee and hip replacement (65); 
in 2011, it was approved by the FDA for thrombosis prophylaxis 
to reduce the risk of DVT and PE following knee and hip replace-
ment surgery. Dabigatran showed non-inferiority to enoxaparin 
in 3 out of 4 trials for high-risk orthopedic patients but has not 
been approved for thrombosis prophylaxis in this population (60).
Mechanisms of venous thrombosis
In the 19th century, the noted physician Virchow proposed a triad 
of physiological alterations that increase the risk of VTE: changes 
in blood flow, in the blood itself, and in the endothelial cells lining 
the blood vessel (66).
Reduced blood flow and stasis
Reduced blood flow and stasis allow the accumulation of procoagu-
lant proteases, such as thrombin, that may overcome the local anti-
coagulant pathways and induce thrombosis. Reduced blood flow 
and stasis may explain the increased rate of VTE associated with 
surgery, hospitalization, paralysis, long-haul travel, cancer, obesity, 
age, and pregnancy (15, 18–20, 25, 28–30). Interestingly, there is 
a left-sided predominance of proximal thrombosis during preg-
nancy that is thought to be due to an acquired compression of the 
left common iliac vein by the presence of the fetus (67). Similarly, 
individuals with May-Thurner syndrome suffer from compression 
of left common iliac vein that increases the risk of DVT (68).
Recently, investigators have developed a new mouse model of 
venous thrombosis that involves stenosis rather than complete 
ligation of the inferior vena cava (69–71). In this model, the lumen 
of the vessel is reduced by 80%–90%, but the procedure does not 
denude the endothelium; however, the endothelium is activated 
and releases vWF and P-selectin from Weibel-Palade bodies that 
capture leukocytes and platelets (69, 70). P-selectin glycoprotein 
ligand-1 (PSGL-1) that is expressed on leukocytes binds to P-selec-
Figure 1
Activation of the coagulation cascade. The 
coagulation cascade can be divided into the 
extrinsic (TF, FVIIa), intrinsic (FXIIa, FXIa, 
FIXa), and common (FXa and thrombin) path-
ways. The FIXa and FXa cofactors (FVIIIa and 
FVa, respectively) are not shown. Pathologi-
cal activation of the extrinsic pathway is via 
TF expression in activated monocytes, mono-
cyte-derived MVs, and possibly activated 
endothelial cells. Cellular RNA and polyphos-
phate (PolyP) released from activated plate-
lets or bacteria activate FXIIa in the intrinsic 
pathway. The two new FDA-approved anti-
coagulant drugs rivaroxaban and dabigatran 
inhibit FXa and thrombin, respectively.
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tin on the endothelium, whereas GP1bα on the surface of plate-
lets interacts with vWF (72, 73). In humans, the most likely site 
of thrombus initiation is the valve pocket sinus due to its vortical 
blood flow and low oxygen tension (74). It is proposed that small 
thrombi formed within the valve pocket grow slowly over days or 
weeks and extend along the inside of the vein wall and may eventu-
ally occlude the blood vessel.
Procoagulant changes in the blood
Thrombophilia describes a disorder in which the blood has a ten-
dency to clot. Thrombophilia can be caused by increases in pro-
coagulant proteins, the presence of variant clotting proteins that 
are more procoagulant, decreases in anticoagulant proteins, and/
or decreased fibrinolysis. In addition to the genetic risk factors 
described above, age, major surgery, cancer, pregnancy, hormone 
contraceptives, and obesity also confer susceptibility (3, 7, 13–16, 
19–23, 25). Pregnancy produces a transient hormone-induced 
hypercoagulable state that probably evolved to protect women 
from hemorrhage at childbirth or in the event of miscarriage (20). 
During a normal pregnancy, levels of FVII, FVIII, FX, fibrinogen, 
vWF, and PAI-1 are increased and do not return to baseline until 
8 weeks postpartum (21). Similarly, one study analyzed the use of 
oral hormone contraceptives and found increased levels of FVII, 
FVIII, FX, prothrombin and fibrinogen (23). Obese individuals have 
elevated levels of FVIII, FIX, and PAI-1 that likely contribute to the 
increased risk of VTE (29). Interestingly, monocyte TF expression 
was found to be increased 1 day after surgery to remove tumors 
(17). Similarly, TF expression on peripheral blood mononuclear 
cells has been shown to be increased 1 day after total knee arthro-
plasty (18). Levels of FVIII and fibrinogen were also increased 2–3 
days after surgery (17), which appears to be secondary to inflam-
mation. Importantly, these procoagulant changes in the blood pre-
ceded the peak of VTE that was observed 7 days after surgery (19).
Activation of the endothelium
The endothelial lining of blood vessels plays a critical role in pre-
venting thrombosis by providing a surface that prevents attachment 
of cells and proteins required for clotting (75). An intact and healthy 
endothelium expresses various anticoagulants, such as TF path-
way inhibitor, thrombomodulin, endothelial protein C receptor, 
and heparin-like proteoglycans (76). In addition, endothelial cells 
express the ectonucleotidase CD39/NTPDase1, which metabolizes 
the platelet agonist ADP. Finally, endothelial cells release the plate-
let inhibitors nitric oxide and prostacyclin (75, 77, 78). However, 
activated endothelial cells downregulate expression of the antico-
agulant protein thrombomodulin and upregulate expression of the 
procoagulant protein TF (79). Activation also leads to the expres-
sion of various adhesion molecules on the surface of the endotheli-
um, such as P-selectin, E-selectin, and vWF, that capture leukocytes, 
platelets, and MVs (80, 81). Hypoxia has been shown to promote the 
release of vWF from Weibel-Palade bodies in endothelial cells (82).
Valve pockets as a site of thrombus initiation
Blood is returned from the venous system of the lower limbs to the 
heart by the calf muscles in the legs acting as pumps. In addition, 
valves in the large veins prevent reflux of the blood. However, the 
valve sinus is prone to thrombosis because of the irregular patterns 
of blood flow and the potential for a low oxygen tension, especially 
during immobilization or long-haul travel (74). Experimental stasis 
has been shown to result in a significant decline in oxygen tension 
in the sinus (83). Interestingly, the number of valves in individu-
als can vary, and those with more valves have a higher frequency of 
DVT (84). Finally, studies that analyzed non-trauma-related venous 
thrombi by autopsy and phlebography concluded that they originat-
ed in the valves and sinuses of the calf veins (74). To protect against 
thrombosis, endothelial cells lining the valve sinus express higher lev-
els of the anticoagulant proteins thrombomodulin and endothelial 
cell protein C receptor and lower levels of vWF compared with those 
of venous endothelial cells (85). My group believes that this protec-
tive pathway becomes overwhelmed under pathological conditions.
TF as a trigger for venous thrombosis
At present, the triggers for venous thrombosis are unknown. How-
ever, it is tempting to speculate that the potent procoagulant TF 
Figure 2
Proposed mechanisms for venous thrombosis. My group proposed that formation of a venous thrombosis can be divided into distinct steps. 
First, the endothelium is activated by hypoxia and/or inflammatory mediators and expresses the adhesion proteins P-selectin, E-selectin, and 
vWF. Second, circulating leukocytes, platelets, and TF+ MVs bind to the activated endothelium. Third, the bound leukocytes become activated 
and express TF. The local activation of the coagulation cascade overwhelms the protective anticoagulant pathways and triggers thrombosis. The 
fibrin-rich clot also contains platelets and red blood cells.
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plays a key role in some forms of VTE because under pathological 
conditions it is present on circulating monocytes, MVs, and pos-
sibly activated endothelium (40). Activated monocytes and tumor 
cells are the primary sources of TF-positive MVs in the circulation 
(43). One may propose that the first step in venous thrombosis 
is activation of the endothelium and expression of the adhesion 
receptors P-selectin and E-selectin as well as vWF (Figure 2). The 
activated endothelium then captures circulating leukocytes, TF-
positive MVs, and platelets. Finally, induction of TF expressed by 
the bound leukocytes together with TF on MVs triggers thrombo-
sis. This hypothesized sequence of events is supported by recent 
studies using a mouse inferior cava stenosis model (70). It was 
found that a genetic deficiency of TF in either hematopoietic cells 
or myeloid cells dramatically reduced venous thrombosis, which 
indicates that TF expression by leukocytes and possibly leukocyte-
derived MVs initiated thrombosis in this model (70). Monocytes 
— and to a lesser extent neutrophils — in the thrombus expressed 
TF. This study also demonstrated a role for FXII and platelets in 
the propagation of the thrombus (70).
Importantly, major surgery is associated with an induction of 
TF expression by circulating monocytes (18). In addition, studies 
have shown that patients with cancer and mice containing tumors 
have high levels of tumor-derived, TF-positive MVs (86–91). One 
study demonstrated binding of tumor-derived MVs to an injured 
blood vessel and increased thrombosis in mice with tumors (92). In 
addition, levels of TF-positive MVs increased prior to VTE in two 
patients with pancreatic cancer in a small prospective study (93). 
However, TF is not the only factor that may trigger thrombosis; 
recent studies have also shown roles for vWF, platelets, extracellular 
chromatin from neutrophils, and even red blood cells in venous 
thrombosis in animal models (Figure 2 and refs. 69, 70, 94–96).
Receptor-mediated binding of leukocytes and MVs  
to activated endothelium
P-selectin appears to be a key endothelial cell receptor that cap-
tures circulating leukocytes and leukocyte-derived MVs express-
ing PSGL-1 (Figure 2) (72). In a mouse microvascular thrombosis 
model, docking of leukocyte-derived MVs to the site of thrombus 
was shown to require P-selectin, and thrombosis was reduced 
in mice deficient in either P-selectin or PSGL-1 (33, 97). Hema-
topoietic cell–derived, TF-positive MVs have been shown to play 
an important role in this microvascular thrombosis model (98). 
Importantly, inhibition of platelet P-selectin also blocked the 
recruitment of leukocytes and reduced fibrin deposition in a 
baboon model of thrombosis (99). More recently, it was shown 
that an oral P-selectin inhibitor reduced thrombosis in a baboon 
stasis model (100). Inhibition of P-selectin also reduced thrombo-
sis in tumor-bearing mice (93). A pan-selectin inhibitor that has 
primary activity against E-selectin reduced thrombosis in an elec-
trolytic inferior vena cava mouse model (101). In addition, neu-
trophils promote thrombosis by releasing serine proteases that 
inactivate the anticoagulant TF pathway inhibitor (102). These 
studies suggest that blocking the binding of leukocytes and MVs 
to the activated endothelium may represent a novel strategy to 
reduce VTE. However, it is important to note that leukocytes also 
play a role in the resolution of venous thrombi, which may limit 
this therapeutic approach to prevention rather than treatment of 
venous thrombosis (103, 104).
Statins and VTE
Statins are commonly used to treat hyperlipidemic patients and 
reduce the incidence of arterial thrombosis. Interestingly, recent 
studies found that statins also reduce VTE (105–108). A meta-
analysis of 8 observational studies concluded that statins reduce 
the risk of VTE but cautioned that additional randomized con-
trolled trials should be performed (109). One study randomized 
a group of over 17,000 healthy men and women with normal low-
density lipoprotein cholesterol levels but high inflammation and 
treated them with rosuvastatin or placebo (110). The statin group 
exhibited a 43% reduction in the rate of VTE compared with that 
of the control group. At present, the mechanism by which statins 
reduce VTE is unclear, but the authors speculated that one mecha-
nism may be the reduction of monocyte TF expression. Indeed, 
statins have been shown to inhibit TF expression in monocytes in 
vitro and in vivo (111–115). My group recently found that simv-
astatin reduced peripheral blood mononuclear cell TF expression 
and TF-positive MVs in hyperlipidemic monkeys, without affect-
ing plasma cholesterol levels (115). Taken together, these results 
suggest that the anticoagulant activity of statins is mediated, in 
part, by their ability to inhibit monocyte TF expression.
Conclusions and future studies
Changes in blood flow, in the blood itself, and in the endothe-
lium all increase the risk of VTE. New studies indicate roles for 
leukocytes, platelets, and MVs in the initiation and propagation 
of the thrombus and suggest that inhibition of the binding of 
leukocytes and MVs to the activated endothelium may repre-
sent a new therapeutic strategy to reduce the risk of VTE. These 
approaches, along further study of the antithrombotic activity of 
statins, suggest that improved therapies for this common disease 
may soon be available.
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